


Enzalutamide (MDV3100)

(For Research Use Only)

Product name	Enzalutamide
Catalog number	30-0005
Synonym(s)	MDV 3100; brand name: Xtandi
Introduction	Enzalutamide is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer. In August 2012, the U.S. Food and Drug Administration approved enzalutamide for the treatment of castration-resistant prostate cancer.
Chemical structure	 <p>The chemical structure of Enzalutamide (MDV3100) is a 5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl core. One nitrogen atom of the imidazolidinone ring is substituted with a 2-fluoro-N-methylbenzamide group, and the other nitrogen atom is substituted with a 3-(4-cyano-3-(trifluoromethyl)phenyl)phenyl group.</p>
CAS#:	915087-33-1
Chemical Formula:	C ₂₁ H ₁₆ F ₄ N ₄ O ₂ S
Molecular Weight	464.09
IUPAC/Chemical name:	4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
Purity	99.0%
Size	10 mg, 50 mg, 100 mg
Appearance	White solid powder
Solubility	Soluble in DMF, DMSO
Storage condition	Short term storage (weeks): 0-4°C under dry conditions Long term storage (months):-20°C under dry conditions